Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]

This section is Partnership Content supplied The content in this section is supplied by GlobeNewswire for the purposes of distributing…

After paying out nearly 1,500 advances of between $1,000 and $10m+ to date, and with access to ‘hundreds of millions of dollars’ in funding, beatBread launches Deal Comparison Tool for indie artists and labels

beatBread has been making a lot of noise in the independent music funding space over the past four years. Founded…